DK0669127T3 - Farmaceutisk præparat med forlænget virkning - Google Patents

Farmaceutisk præparat med forlænget virkning

Info

Publication number
DK0669127T3
DK0669127T3 DK93924826T DK93924826T DK0669127T3 DK 0669127 T3 DK0669127 T3 DK 0669127T3 DK 93924826 T DK93924826 T DK 93924826T DK 93924826 T DK93924826 T DK 93924826T DK 0669127 T3 DK0669127 T3 DK 0669127T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical preparation
tetrone
azatricyclo
methoxycyclohexyl
octa
Prior art date
Application number
DK93924826T
Other languages
English (en)
Inventor
Akira Kagayama
Sumihisa Kimura
Saburo Murata
Sachiyo Tanimoto
Takehisa Hata
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Application granted granted Critical
Publication of DK0669127T3 publication Critical patent/DK0669127T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
DK93924826T 1992-11-18 1993-11-11 Farmaceutisk præparat med forlænget virkning DK0669127T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP30888592 1992-11-18
PCT/JP1993/001672 WO1994010981A1 (en) 1992-11-18 1993-11-11 Prolonged-action pharmaceutical preparation

Publications (1)

Publication Number Publication Date
DK0669127T3 true DK0669127T3 (da) 1999-12-06

Family

ID=17986438

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93924826T DK0669127T3 (da) 1992-11-18 1993-11-11 Farmaceutisk præparat med forlænget virkning

Country Status (11)

Country Link
US (1) US5601844A (da)
EP (1) EP0669127B1 (da)
JP (1) JP3520517B2 (da)
CN (1) CN1093571A (da)
AT (1) ATE183083T1 (da)
AU (1) AU5434094A (da)
DE (1) DE69326015T2 (da)
DK (1) DK0669127T3 (da)
ES (1) ES2134860T3 (da)
GR (1) GR3031179T3 (da)
WO (1) WO1994010981A1 (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06345646A (ja) * 1993-06-08 1994-12-20 Fujisawa Pharmaceut Co Ltd ローション剤
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US20060280774A1 (en) * 1995-06-02 2006-12-14 Allergan, Inc. Compositions and methods for treating glaucoma
US5910492A (en) * 1995-06-05 1999-06-08 Takeda Chemical Industries, Ltd. Osteogenic promoting pharmaceutical composition
ATE254450T1 (de) 1995-09-19 2003-12-15 Fujisawa Pharmaceutical Co Aerosolzusammensetzungen
ZA9710927B (en) 1996-12-06 1998-06-15 Fujisawa Pharmaceutical Co Pharmaceutical composition.
US5849800A (en) * 1997-03-28 1998-12-15 The Penn State Research Foundation Use of amantadine for treatment of Hepatitis C
US6127520A (en) 1997-04-15 2000-10-03 Regents Of The University Of Michigan Compositions and methods for the inhibition of neurotransmitter uptake of synaptic vesicles
US6113738A (en) * 1998-03-16 2000-09-05 Nalco Chemical Company Use of additives to breakdown and stabilize wax during fiber recycle
CA2319431C (en) 1998-03-16 2008-01-22 Nalco Chemical Company Contaminant dispersants useful in recycling of treated containers
WO1999049863A1 (fr) * 1998-03-26 1999-10-07 Fujisawa Pharmaceutical Co., Ltd. Preparations a liberation prolongee
US6399649B1 (en) 1998-09-24 2002-06-04 Boston Medical Center Corporation Compositions and methods for the treatment of chronic lymphocytic leukemia
US7732404B2 (en) * 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
AU3649502A (en) 2000-11-29 2002-06-11 Oculex Pharm Inc Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
PT1539157E (pt) 2002-09-18 2013-10-04 Univ Pennsylvania Rapamicina para utilização na inibição ou prevenção de neovascularização coroidal
US20050048099A1 (en) * 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
DK1663217T3 (da) * 2003-08-29 2010-11-08 Lifecycle Pharma As Faste dispersioner indeholdende tacrolimus
EP1663216B1 (en) 2003-08-29 2011-11-02 Veloxis Pharmaceuticals A/S Modified release compositions comprising tacrolimus
US7585517B2 (en) * 2003-09-18 2009-09-08 Macusight, Inc. Transscleral delivery
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
BRPI0608152A2 (pt) 2005-02-09 2009-11-10 Macusight Inc formulações para tratamento ocular
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
US20070178138A1 (en) * 2006-02-01 2007-08-02 Allergan, Inc. Biodegradable non-opthalmic implants and related methods
WO2007092620A2 (en) 2006-02-09 2007-08-16 Macusight, Inc. Stable formulations, and methods of their preparation and use
CA2645488C (en) 2006-03-23 2014-09-02 Macusight, Inc. Formulations comprising rapamycin and methods using same for vascular permeability-related diseases or conditions
US20070298073A1 (en) * 2006-06-23 2007-12-27 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8802128B2 (en) * 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
CA2688381C (en) 2007-05-30 2016-10-11 Lifecycle Pharma A/S Once daily oral dosage form comprising tacrolimus
US8222272B2 (en) 2008-04-11 2012-07-17 Roxane Laboratories, Inc. Pharmaceutical formulation and process comprising a solid dispersion of macrolide (tacrolimus)
PT2575769T (pt) 2010-02-17 2016-09-22 Veloxis Pharmaceuticals As Composição de tacrolímus estabilizada
AR101476A1 (es) 2014-08-07 2016-12-21 Acerta Pharma Bv Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8430455D0 (en) * 1984-12-03 1985-01-09 Fujisawa Pharmaceutical Co Fr-900506 substance
GB8608080D0 (en) * 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
JPS63122620A (ja) * 1986-11-12 1988-05-26 Sanraku Inc ポリ乳酸マイクロスフエア及びその製造方法
EP0346427B1 (en) * 1987-12-09 1995-03-29 FISONS plc Macrocyclic compounds
US5196437A (en) * 1990-02-13 1993-03-23 Fujisawa Pharmaceutical Company, Ltd. Method for treating hepatic diseases and regenerating liver tissue using FK 506 and related compounds
CA2012978C (en) * 1990-02-13 2002-02-26 Thomas E. Starzl Treatment of hepatic diseases using fk 506 and related compounds
US5260301A (en) * 1990-03-01 1993-11-09 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutical solution containing FK-506
JPH0449232A (ja) * 1990-06-15 1992-02-18 Fujisawa Pharmaceut Co Ltd 懸濁用組成物または懸濁液並びにそれらの製造法
ATE150304T1 (de) * 1990-09-04 1997-04-15 Fujisawa Pharmaceutical Co Tricyclische verbindungen enthaltende salben
IE65341B1 (en) * 1990-11-08 1995-10-18 Fujisawa Pharmaceutical Co Suspensions containing tricyclic compounds

Also Published As

Publication number Publication date
WO1994010981A1 (en) 1994-05-26
CN1093571A (zh) 1994-10-19
DE69326015T2 (de) 2000-02-03
US5601844A (en) 1997-02-11
EP0669127B1 (en) 1999-08-11
EP0669127A4 (en) 1995-11-02
ATE183083T1 (de) 1999-08-15
AU5434094A (en) 1994-06-08
JP3520517B2 (ja) 2004-04-19
DE69326015D1 (de) 1999-09-16
ES2134860T3 (es) 1999-10-16
EP0669127A1 (en) 1995-08-30
GR3031179T3 (en) 1999-12-31

Similar Documents

Publication Publication Date Title
DK0669127T3 (da) Farmaceutisk præparat med forlænget virkning
IL100011A0 (en) Suspendible pharmaceutical composition containing a tricyclic compound and processes for the preparation thereof
DK0474126T3 (da)
IL94971A0 (en) Aqueous pharmaceutical composition containing a tricyclic compound and processes for the preparation thereof
MX9202945A (es) Composicion consistente en una dispersion solida de la sustancia fr-900506.
ATE119041T1 (de) Wässrige flüssige arzneizubereitungen.